correct in that the NRCAC group aren't really relevant for efficacy, as they weren't randomized. This would be true if this was the CANVAS trial. But, it is a pilot trial, so it can be used to generate some sort of statistic for a power calculation.
The fact that they were in the trial doesn't matter, as it only matters when they progressed. The fact they have a higher PFS isnt due to being in the trial first, as half of them have already progressed. Its unfortunate that the non-randomized subjects are performing the best!
What is a concern, and i posted this in another thread, is that the control group in the first remission participants have not had enough progressions. it looks like first remission people are not the ideal candidates for CVAC. They still require 3-4 more progressions before a median PFS stat can be generated, so not looking good.
What is encouraging is the second remission statistic. This has not yet been generated in the CVAC group, and if you look at the data, it only requires 1 person to progress before this can be generated. If that happens today, that would mean PFS would be about 400 days, compared to the 145 in the OSC. The longer they take to progress the better!
PRR Price at posting:
12.3¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)